Abstract
TGF-β2 secretion by high grade gliomas has been implicated as one of the major factors contributing to tumor growth, alterations in the host immune response to tumor, and failure of gliomas to respond to current immunotherapy strategies. We hypothesized that targeted delivery and inhibition of TGF-β2 by TGF-β2 antisense oligonucleotides (AS-ODNs) would overcome tumor-induced immunosuppression and enhance the capacity of tumor vaccines to eradicate established brain tumors. Utilizing the mRNA sequences of TGF-β2, specific AS-ODNs were constructed and tested for their ability to inhibit TGF-β2 production in 9L glioma cells. The effect of combining local intracranial administration of antisense ODNs with systemic tumor vaccine was examined. Fisher 344 rats were vaccinated subcutaneously with irradiated 9L tumor cells 3 days after intracranial tumor implantation. Four days after vaccination, ODNs were administered into the tumor mass and survival was followed. ODNs delivered locally distributed widely within the brain tumor mass and inhibited TGF-β2 expression. Survival of tumor-bearing rats treated with the combination of local antisense and systemic tumor vaccine was significantly enhanced (mean survival time (MST): 48.0 days). In contrast, MST for animals treated with nonsense plus vaccine, vaccine alone, antisense alone or PBS showed no survival advantage and no statistical differences between groups (33.5 days, 29.0 days, 37.5 days, and 31.5 days, respectively). Our data supports the hypothesis that local administration of antisense TGF-β2 ODNs combined with systemic vaccination can increase efficacy of immunotherapy and is a novel, potentially clinically applicable, strategy for high-grade glioma treatment.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Scheinberg LC, Suzuki K, Edelman F, Davidoff LM (1963) Studies in immunization against a transplantable cerebral mouse glioma. J Neurosurg 20:312–316
Kida Y, Cravioto H, Hochwald GM, Hochgeschwender U, Ransohoff J (1983) Immunity to transplantable nitrosourea-induced neurogenic tumors. II. Immunoprophylaxis of tumors of the brain. J Neuropathol Exp Neurol 42:122–135
Yumitori K, Ito Y, Handa H (1982) Protective effect of immunization with virus-infected glioma cells against intracerebrally implanted glioma in mice. Eur J Cancer Clin Oncol 18:177–181
Siesjo P, Visse E, Lindvall M, Salford L, Sjogren HO (1993) Immunization with mutagen-treated (tum-) cells causes rejection of nonimmunogenic rat glioma isografts. Cancer Immunol Immunother 37:67–74
Glick RP, Lichtor T, Kim TS, Ilangovan S, Cohen E (1995) Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo. Neurosurgery 36:548–555
Broder H, Anderson A, Odesa SK, Kremen TJ, Liau LM (2001) Recombinant adenovirus-transduced dendritic cell immunization in a murine model of central nervous system tumor. Neurosurgical Focus 9:1–8
Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee␣PK, Yong WH, Incardona F, Thompson RC, Riedinger MS, Zhang W, Prins RM, Black KL (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:842–847
Siesjo P, Visse E, Sjogren HO (1996) Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment. J Immunother Emphasis Tumor Immunol 19:334–345
Bloom WH, Carstairs KC, Crompton MR, McKissock W (1960) Autologous glioma transplantation. Lancet 2:77–78
Trouillas P, Lapras C (1970) [Active immunotherapy of cerebral tumor. 20 cases]. Neurochirurgie 16:143–170
Mahaley MSJ, Bigner DD, Dudka LF, Wilds PR, Williams DH, Bouldin TW, Whitaker JN, Bynum JM (1983) Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic human glioma cells: a pilot study. J Neurosurg 59:201–207
Roszman T, Elliott L, Brooks W (1991) Modulation of T-cell function by gliomas. Immunol Today 12:370–374
Brooks WH, Netsky MG, Normansell DE, Horwitz DA (1972) Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J Exp Med 136:1631–1647
Mahaley MSJ, Brooks WH, Roszman TL, Bigner DD, Dudka L, Richardson S (1977) Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. J Neurosurg 46:467–476
Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I, Fontana A (1989) Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol 143:3222–3229
Brooks WH, Latta RB, Mahaley MS, Roszman TL, Dudka L, Skaggs C (1981) Immunobiology of primary intracranial tumors. Part 5: correlation of a lymphocyte index and clinical status. J Neurosurg 54:331–337
Kuppner MC, Sawamura Y, Hamou MF, de Tribolet N (1990) Influence of PGE2- and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2-activated lymphocytes. J Neurosurg 72:619–625
Hishii M, Nitta T, Ishida H, Ebato M, Kurosu A, Yagita H, Sato K, Okumura K (1995) Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery 37:1160–1166
Kuppner MC, Hamou MF, Sawamura Y, Bodmer S, de Tribolet N (1989) Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2. J␣Neurosurg 71:211–217
Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades HN (1992) Effect of the expression of transforming growth factor-beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J Neurosurg 76:799–804
Huber D, Philipp J, Fontana A (1992) Protease inhibitors interfere with the transforming growth factor-beta-dependent but not the transforming growth factor-beta-independent pathway of tumor cell-mediated immunosuppression. J␣Immunol 148:277–284
Kehrl JH, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB, Fauci AS (1986) Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol 137:3855–3860
Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS (1986) Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 163:1037–1050
Ranges GE, Figari IS, Espevik T, Palladino MAJ (1987) Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med 166:991–998
Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn␣MB, Burlington DB, Lane HC, Fauci AS (1986) Effects of transforming growth factor beta on the functions␣of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 136:3916–3920
Kuppner MC, Hamou MF, Bodmer S, Fontana A, de Tribolet N (1988) The glioblastoma-derived T-cell suppressor factor/transforming growth factor beta 2 inhibits the generation of␣lymphokine-activated killer (LAK) cells. Int J Cancer 42:562–567
Miescher S, Whiteside TL, de Tribolet N, von FV (1988) In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J Neurosurg 68:438–448
Miescher S, Whiteside TL, Carrel S, von FV (1986) Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J␣Immunol 136:1899–1907
Zuber P, Kuppner MC, de Tribolet N (1988) Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells. Eur J Immunol 18:1623–1626
Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R, Rubin R (1994) Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 54:2218–2222
Jensen RL (1998) Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol 49:189–195
Satoh E, Naganuma H, Sasaki A, Nagasaka M, Ogata H, Nukui H (1997) Effect of irradiation on transforming growth factor beta secretion by malignant glioma cells. J Neurooncol 33:195–200
Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black␣KL, Royston I, Sobol RE (1996) Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 93:2909–2914
Bogdahn U, Hau P, Brawanski A, Schlaier J, Mehdorn M, Wurm G, Pickler J, Kunst M, Stauder G, Schlingensiepen K-H (2004) J Clin Oncol 22(14S):1514
Wagner RW (1994) Gene inhibition using antisense oligodeoxynucleotides. Nature 372:333–335
Sharma HW, Narayanan R (1995) The therapeutic potential of antisense oligonucleotides. Bioessays 17:1055–1063
Hall WA, Flores EP, Low WC (1996) Antisense oligonucleotides for central nervous system tumors. Neurosurgery 38:376–383
Engelhard HH, Egli M, Rozental JM (1998) Use of antisense vectors and oligodeoxynucleotides in neuro-oncology. Pediatr Neurosurg 28:279–285
Carpentier AF, Xie J, Mokhtari K, Delattre JY (2000) Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 6:2469–2473
Engelhard H, Narang C, Homer R, Duncan H (1996) Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: in vitro and in vivo studies of uptake, effects and toxicity. Biochem Biophys Res Commun 227:400–405
Liu Y, Ng K, Lillehei KO (2000) Time course analysis and modulating effects of established brain tumor on active-specific immunotherapy. Neurosurg Focus 9:1–9
Olofsson A, Miyazono K, Kanzaki T, Colosetti P, Engstrom U, Heldin CH (1992) Transforming growth factor-beta 1, -beta 2, and -beta 3 secreted by a human glioblastoma cell line. Identification of small and different forms of large latent complexes. J Biol Chem 267:19482–19488
Koishi K, Dalzell KG, McLennan IS (2000) The expression and structure of TGF-beta2 transcripts in rat muscles. Biochim Biophys Acta 1492(2–3):311–319
Agrawal S, Temsamani J, Tang JY (1991) Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 88:7595–7599
Lillehei KO, Liu Y, Kong Q (1999) Current perspectives in immunotherapy. Ann Thorac Surg 68:S28–S33
Lillehei KO, Kong Q, Withrow SJ, Kleinschmidt-DeMasters BK (1996) Efficacy of intralesionally administered cisplatin-impregnated biodegradable polymer for the treatment of 9L gliosarcoma in the rat. Neurosurgery 39(6):1191–1197
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 457–481
Matthews DE, Farewell V (1985) The Log-Rank or Mantel-Haenszel test for the comparison of survival curves. In: Anonymous using and understanding medical statistics, Basel, Karger, pp 79–87
Jachimczak P, Bogdahn U, Schneider J, Behl C, Meixensberger J, Apfel R, Dorries R, Schlingensiepen KH, Brysch W (1993) The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J␣Neurosurg 78:944–951
Gorelik L, Flavell RA (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7:1118–1122
Ruffini PA, Rivoltini L, Silvani A, Boiardi A, Parmiani G (1993) Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol Immunother 36(6):409–416
Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D (1996) Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 2(6):668–675
Unsicker K, Flanders KC, Cissel DS, Lafyatis R, Sporn MB (1991) Transforming growth factor beta isoforms in the adult rat central and peripheral nervous system. Neuroscience 44:613–625
Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH (1986) Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83:4167–4171
Jachimczak P, Hessdorfer B, Fabel-Schulte K, Wismeth C, Brysch W, Schlingensiepen KH, Bauer A, Blesch A, Bogdahn U (1996) Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int J Cancer 65:332–337
Grzanna R, Dubin JR, Dent GW, Ji Z, Zhang W, Ho SP, Hartig PR (1998) Intrastriatal and intraventricular injections of oligodeoxynucleotides in the rat brain: tissue penetration, intracellular distribution and c-fos antisense effects. Brain Res Mol Brain Res 63:35–52
Szklarczyk A, Kaczmarek L (1995) Antisense oligodeoxyribonucleotides: stability and distribution after intracerebral injection into rat brain. J Neurosci Methods 60:181–187
Broaddus WC, Prabhu SS, Gillies GT, Neal J, Conrad WS, Chen ZJ, Fillmore H, Young HF (1998) Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion. J Neurosurg 88:734–742
Whitesell L, Geselowitz D, Chavany C, Fahmy B, Walbridge S, Alger JR, Neckers LM (1993) Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. Proc Natl Acad Sci USA 90:4665–4669
Patel AR, Li J, Bass BL, Wang JY (1998) Expression of the transforming growth factor-beta gene during growth inhibition following polyamine depletion. Am J Physiol 275:C590–C598
Stein CA, Cheng YC (1993) Antisense oligonucleotides as therapeutic agents—is the bullet really magical? Science 261:1004–1012
Dutta T, Spence A, Lampson LA (2003) Robust ability of IFN-gamma to upregualte class II MHC antigen expression in tumor bearing rat brains. J Neuro-Oncol 64(1–2):31–44
Lampson LA, Wen P, Roman VA, Morris JH, Sarid JA (1992) Disseminating tumor cells and their interactions with leukocytes visualized in the brain. Cancer Res 52(4):1018–1025
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported in part by the University of Colorado Cancer Center, a generous grant from the Partridge family, the Milheim Foundation for Brain Tumor Research, the ABC2 Foundation, the Michele Plachy-Rubin Foundation for Brain Tumor Research, and a generous grant from the Pharmaceutical Research and Manufacturers of America Foundation.
Rights and permissions
About this article
Cite this article
Liu, Y., Wang, Q., Kleinschmidt-DeMasters, B.K. et al. TGF-β2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors. J Neurooncol 81, 149–162 (2007). https://doi.org/10.1007/s11060-006-9222-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-006-9222-1